EpiEndo announces the successful completion of COPD trial – with help from the MEU

EpiEndo’s Phase 2A investigation delved into the safety and tolerance of EP395.

Over 12 weeks, COPD patients received EP395 once daily in capsule form, while researchers monitored its impact on various biomarkers.

The study, spanning six clinics in the UK and Germany, enrolled 61 adults diagnosed with COPD.

Spearheading the research were renowned experts: Professor Henrik Watz from the Pulmonary Research Institute at the Lungen Clinic, and our very own Professor Dave Singh, Respiratory Pharmacology Professor at the University of Manchester and Medical Director at The Medicines Evaluation Unit.

The study results show EP395 to have tolerability and safety as well as beneficial effects on inflammatory biomarkers, as seen with antibiotic macrolides. 

CEO David Rogers, MEU –  “We are pleased to play our part as a clinical site in helping EP395 on its development journey towards helping future COPD patients.“

Read more in EpiEndo’s full press release.